Clinical trial · Observational
Long-term KRd in Relapsed and/or Refractory Multiple Myeloma
Real-world Evidence of Carfilzomib, Lenalidomide, Dexamethasone Combination Therapy in Korean Relapsed and/or Refractory Multiple Myeloma Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Research question: Is KRd therapy effective and safe in the real-world Asian patients? Primay objective: To evaluate the effectiveness of KRd in RRMM patients Secondary objectives: To evaluate the effectiveness of investigational treatment strategy by * PFS difference according to the high-risk disease subgroups and previous treatment * OS * Overall response rate and clinical benefit rate * Duration of response To evaluate the safety and tolerability of KRd in RRMM patients
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma in Relapse | Multiple Myeloma | CURATED_BROADER | 0.78 |
| Multiple Myeloma, Refractory | Multiple Myeloma | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carfilzomib | Drug | Carfilzomib | ALIAS |
| Dexamethasone | Drug | Dexamethasone | ALIAS |
| Lenalidomide | Drug | Lenalidomide | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Relapsed and/or refractory multiple myeloma
- description
- Multiple myeloma in relapsed but not refractory, relapsed and refractory, and primary refractory status
- interventionNames
- Drug: Carfilzomib
- Drug: Lenalidomide
- Drug: Dexamethasone
Primary outcomes (1)
- measure
- Progression-free survival
- timeFrame
- up to 54 months
- description
- the time from the first date of KRd to the date of disease progression or death or censored date
Secondary outcomes (4)
- measure
- Overall survival
- timeFrame
- up to 54 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion criteria 1. Patients ≥ 19 years 2. Relapsed and/or refractory multiple myeloma patients 3. Patients who had received KRd combination chemotherapy from February, 2018 to February, 2020. Exclusion criteria 1. Patient who had not been treated with KRd combination therapy from the first cycle of treatment 2. Patients who had received KRd combination chemotherapy before February, 2018 and after February, 2020.
References
Publications (1)
- BACKGROUNDStewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6. PMID 25482145